Key Highlights
- Novo Nordisk's chief executive said he sees real upside to trading the company's shares directly on the New York Stock Exchange, doing away with the depositary receipt structure US investors rely on today.
- More than half of Novo's sales now come from the US, where its diabetes and obesity treatments generate the bulk of revenue.
- The chief executive said the topic has surfaced periodically over the past decade but hasn't been formally discussed since he took the top Job last year.
- Novo's stock has lost more than 70 percent of its value since a 2023 peak, a stretch during which rival Eli Lilly's shares have climbed.
A Structural Question Doustdar Won't Rule Out
Speaking with the Financial Times, Novo Nordisk (NYSE:NVO) chief executive Mike Doustdar said he's genuinely open to the idea of listing the company's stock directly on the New York Stock Exchange, a change that would retire the American depositary receipt arrangement currently standing between US investors and the underlying shares. Asked point blank whether Novo would consider it, he didn't hedge: "I clearly do see some advantages with that."
His reasoning traces back to where Novo's Shareholder base has actually migrated. Twenty years ago that base sat overwhelmingly in Scandinavia; today, he said, conversations with American investors have become a routine part of running the company, sitting alongside the relationships Novo has cultivated with its longer-tenured backers.
Not a Live Project, But Not Off the Table Either
Doustdar was careful to frame this as exploratory rather than imminent. The idea has come up periodically over roughly the last ten years, he said, but nothing resembling formal internal discussion has happened since he stepped into the CEO role. His instinct, he explained, is to default to curiosity rather than dismissal whenever a structural question like this lands on his desk, weighing the tradeoffs before making any call, while making clear Novo isn't actively pursuing a change right now.
Should Novo eventually move in that direction, it would be following a path UK drugmaker AstraZeneca already took earlier this year, part of a wider pattern of major pharmaceutical companies headquartered outside the US recalibrating how closely tied their Capital Markets identity is to American exchanges.
Why the Timing Matters
More than half of Novo's revenue, and the lion's share of its diabetes and obesity drug sales, now flows from the US market, even as the company fights to reclaim ground in a weight-loss category it essentially created. Novo went public with Wegovy in 2021 and briefly rode that launch to become Europe's single most valuable listed company in 2023, with a market valuation topping USD 600 billion.
That high point looks distant now. Novo's shares have shed more than 70 percent of their value since then, a slide that has run in almost the opposite direction of Eli Lilly's stock over the same window. Data shows that Lilly's competing treatment, Zepbound, outselling Wegovy this year by upward of USD 7 billion, a gap wide enough to keep questions about Novo's US strategy, including how it's structured in American capital markets, firmly in view.






Please wait processing your request...